Abstract: The present invention relates to a pharmaceutical composition for oral administration, particularly in the form of a tablet or a powder suitable to be filled into a capsule shell, comprising 2-(isoindolin-2-ylmethyl)-5-((1-(methylsulfonyl)-piperidin-4-yl)methoxy)-4H-pyran-4-one (I) or a pharmaceutically acceptable salt thereof as an active ingredient. Compound (I) or a pharmaceutically acceptable salt thereof is a selective inhibitor of CYP11A1 enzyme and is useful in the treatment of hormonally regulated diseases such as cancer including prostate cancer and breast cancer.

Abstract: A method includes accessing, by a server computer, a plurality of electronic mail messages; identifying, based on information contained in each electronic mail message, one or more actions that can be taken with respect to each electronic mail message; and outputting, for display at a client computing device, an electronic mail interface. The electronic mail interface includes a message preview element for each electronic mail message. Each message preview element includes an interface element for causing performance of the action for each electronic mail message.

Abstract: A method includes accessing, by a server computer, a plurality of electronic mail messages; identifying, based on information contained in each electronic mail message, one or more actions that can be taken with respect to each electronic mail message; and outputting, for display at a client computing device, an electronic mail interface. The electronic mail interface includes a message preview element for each electronic mail message. Each message preview element includes an interface element for causing performance of the action for each electronic mail message.

Abstract: A method and apparatus for ensuring efficient validation coverage of an architecture, such as protocol or interconnect architecture, is herein described. A coverage space of states for an architecture is generated and stored in a database. During simulation, states of the coverage space encountered are marked. From this, the states encountered and not encountered may be determined. Based on the states not encountered, a targeted test suite is developed to target at least some of the states not encountered during previous simulation. This feedback loop from simulation to refining of a test suite based on states of a coverage space not encountered during simulation may be recursively repeated until adequate validation, i.e. an adequate confidence level of validation, of the coverage space is achieved.